• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Azitra Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/23/25 4:10:27 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZTR alert in real time by email
    false 0001701478 0001701478 2025-06-23 2025-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 23, 2025

     

     

     

    AZITRA, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-41705   46-4478536

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    21 Business Park Drive

    Branford, CT 06405

    (Address of principal executive offices)(Zip Code)

     

    (203) 646-6446

    (Registrant’s telephone number, including area code)

     

     

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock: Par value $0.0001   AZTR   NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders

     

    On June 23, 2025, Azitra, Inc. (the “Company”), convened its 2025 annual meeting of stockholders (the “Annual Meeting”). Proxies had been submitted by stockholders representing over one-third of the shares of the Company’s common stock outstanding and entitled to vote, which constituted a quorum. At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in more detail in the proxy statement for the Annual Meeting (the “Proxy Statement”). As described in more detail below, the polls were left open on an additional proposal in order to allow additional time for the stockholders to vote on such proposal.

     

    Proposal No. 1. Stockholders approved the election of the four director nominees named in the Proxy Statement to serve as members of the Board of Directors of the Company until the next annual meeting of stockholders and until their successors are duly elected and qualified. The director nominees named in the Proxy Statement for election to our Board of Directors are the following individuals: Francisco D. Salva, Travis Whitfill, Barbara Ryan and John Schroer, with shares voted as follows:

     

    Name  For  Withheld 

    Broker

    Non-Votes

    Francisco D. Salva  1,107,896  255,481  7,225,742
    Travis Whitfill  1,120,930  242,447  7,225,742
    Barbara Ryan  1,260,318  103,059  7,225,742
    John Schroer  1,263,148  100,229  7,225,742

     

    Proposal No. 3. Stockholders ratified the appointment of Grassi & Co., CPAs, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, with shares voted as follows:

     

    Votes For  Votes Against  Abstentions  Broker Non-Votes
    8,370,807  151,361  66,951  0

     

    Proposal No. 4. Stockholders approved, for purposes of complying with NYSE American Rule 713(a), of the issuance of more than 19.99% of the Company’s issued and outstanding shares of common stock, including shares of common stock underlying warrants, pursuant to the purchase agreement with Alumni Capital LP, with shares voted as follows:

     

    Votes For  Votes Against  Abstentions  Broker Non-Votes
    1,204,236  155,171  3,970  7,225,742

     

    Stockholders did not vote on Proposal No. 2 (Adoption of an amendment to the Company’s Second Amended and Restated Certificate of Incorporation (as amended) to increase the authorized number of shares of the Company’s common stock from 100,000,000 shares to 200,000,000 shares) at the Annual Meeting. On June 18, 2025, the Company filed a supplement to the Proxy Statement for the Annual Meeting, which updated the disclosure included in the Proxy Statement relating to the applicable voting standard on Proposal No. 2. Accordingly, the Annual Meeting was adjourned in order to allow additional time for the stockholders to vote on Proposal No. 2.

     

    The reconvened Annual Meeting (the “Reconvened Annual Meeting”) will be held virtually on July 3, 2025 at 11:00 a.m., Eastern Time. Stockholders can attend and participate, vote and submit a question at the Reconvened Annual Meeting via the same link previously provided upon registration for the Annual Meeting. Valid proxies submitted prior to the Annual Meeting will continue to be valid for the Reconvened Annual Meeting, unless properly changed or revoked prior to votes being taken at the Reconvened Annual Meeting. The record date of May 28, 2025 will remain the same for the Reconvened Annual Meeting. During the period of the adjournment, the polls for Proposal No. 2 will remain open.

     

    Additional Information and Where to Find It

     

    In connection with the Annual Meeting, the Company filed with the U.S. Securities and Exchange Commission (the “SEC”) a definitive proxy statement of which was mailed to the Company’s stockholders as of the record date for the Annual Meeting. STOCKHOLDERS AND OTHER INTERESTED PERSONS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT, AS WELL AS ALL AMENDMENTS AND SUPPLEMENTS THERETO (INCLUDING THE AMENDMENT FILED WITH THE SEC ON JUNE 18, 2025), BECAUSE IT CONTAINS IMPORTANT INFORMATION ABOUT THE MATTERS BEFORE THE STOCKHOLDERS AT THE ANNUAL MEETING. The Company’s stockholders may also obtain copies of the Proxy Statement, the Annual Report to stockholders and all other relevant documents filed or that will be filed with the SEC in connection with the Annual Meeting, without charge, once available, at the SEC’s website at http://www.sec.gov or by directing a request to: Azitra, Inc., 21 Business Park Drive, Branford, Connecticut 06405.

     

    Participants in the Solicitation

     

    The Company and certain of its respective directors, executive officers, and other members of management and employees may be deemed participants in the solicitation of proxies of the Company’s stockholders in connection with the Annual Meeting. STOCKHOLDERS AND OTHER INTERESTED PERSONS MAY OBTAIN, WITHOUT CHARGE, MORE DETAILED INFORMATION REGARDING THE DIRECTORS AND OFFICERS OF THE COMPANY IN ITS ANNUAL REPORT ON FORM 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024, WHICH WAS FILED WITH THE SEC ON FEBRUARY 24, 2025.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      AZITRA, INC.
         
    Dated: June 23, 2025 By: /s/ Francisco D. Salva
        Francisco D. Salva
        Chief Executive Officer

     

     

    Get the next $AZTR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AZTR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AZTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

      Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application siteTrial is 50% enrolled; six patients have received ATR12-351, a live precision dermatology therapeutic candidate Azitra presenting at the 2025 BIO International ConventionBRANFORD, Conn., June 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced encouraging safety data from the initial clinical trial of its live biotherapeutic candidate, ATR12-351, targeting Netherton syndrome.

      6/17/25 8:02:00 AM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

      BRANFORD, Conn., June 10, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the company will present at the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts. The presentation will highlight recent updates and progress in Azitra's pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome and ATR-04, in development for the treatment of moderate to severe EGFRi-associ

      6/10/25 8:33:00 AM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

      BRANFORD, Conn., May 28, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster describing the Phase 1/2 clinical trial of ATR04-484 in EGFR inhibitor ("EGFRi")-associated rash at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) being held May 30-June 3, 2025 in Chicago. The presentation titled, "Epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity treated with topical application of

      5/28/25 8:33:00 AM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    SEC Filings

    See more
    • Azitra Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders

      8-K - Azitra, Inc. (0001701478) (Filer)

      7/3/25 4:05:46 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Azitra, Inc. (0001701478) (Filer)

      6/23/25 4:10:27 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Azitra, Inc. (0001701478) (Filer)

      6/18/25 5:21:29 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Staskey Norm bought $10,034 worth of shares (47,600 units at $0.21), increasing direct ownership by 1,360% to 51,100 units (SEC Form 4)

      4 - Azitra, Inc. (0001701478) (Issuer)

      4/1/24 9:51:59 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Staskey Norm bought $10,034 worth of shares (47,600 units at $0.21), increasing direct ownership by 1,360% to 51,100 units (SEC Form 4)

      4 - Azitra, Inc. (0001701478) (Issuer)

      4/1/24 9:51:59 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Leadership Updates

    Live Leadership Updates

    See more
    • Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

      BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies. "We are delighted to welcome Travis back to Azitra full time, after his tenure of nearly ten years in biotech venture capital," said Francisco Salva, President and CEO of Azitra. "Travis brings a wealth of knowledge in biotech, synthetic biology, and drug development. He will

      7/11/23 4:05:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Azitra Inc

      SC 13G/A - Azitra, Inc. (0001701478) (Subject)

      11/14/24 12:56:51 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Azitra Inc

      SC 13G/A - Azitra, Inc. (0001701478) (Subject)

      11/14/24 12:18:21 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Azitra Inc

      SC 13G/A - Azitra, Inc. (0001701478) (Subject)

      11/6/24 4:35:43 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Financials

    Live finance-specific insights

    See more
    • Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

      BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update. FY 2024 and Recent Business Highlights Initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients; Initial safety data from first set of Netherton syndrome patients expected in the first half of 2025 with topline data from the Phase 1b trial by year-end 2025Received clearance from the U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical stu

      2/24/25 8:30:00 AM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

      BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update. Q3 2024 and Recent Business Highlights: Completed a follow-on offering of $10 million in gross proceedsDosed first Netherton syndrome patient with ATR-12Submitted an IND to the FDA and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitorsReceived Fast Track designat

      11/12/24 5:05:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

      Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones Strengthened global intellectual property portfolio with newly granted and allowed patents Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting Pres

      8/12/24 6:23:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care